Cargando…
Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study
OBJECTIVES: To explore whether changes in a composite (power Doppler/greyscale ultrasound (PDUS)) synovitis score, developed by the OMERACT-EULAR-Ultrasound Task Force, predict disease activity outcomes in rheumatoid arthritis (RA). METHODS: Patients with RA who were methotrexate inadequate responde...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860864/ https://www.ncbi.nlm.nih.gov/pubmed/27175297 http://dx.doi.org/10.1136/rmdopen-2015-000237 |
_version_ | 1782431134394613760 |
---|---|
author | D'Agostino, Maria-Antonietta Boers, Maarten Wakefield, Richard J Berner Hammer, Hilde Vittecoq, Olivier Filippou, Georgios Balint, Peter Möller, Ingrid Iagnocco, Annamaria Naredo, Esperanza Østergaard, Mikkel Gaillez, Corine Le Bars, Manuela |
author_facet | D'Agostino, Maria-Antonietta Boers, Maarten Wakefield, Richard J Berner Hammer, Hilde Vittecoq, Olivier Filippou, Georgios Balint, Peter Möller, Ingrid Iagnocco, Annamaria Naredo, Esperanza Østergaard, Mikkel Gaillez, Corine Le Bars, Manuela |
author_sort | D'Agostino, Maria-Antonietta |
collection | PubMed |
description | OBJECTIVES: To explore whether changes in a composite (power Doppler/greyscale ultrasound (PDUS)) synovitis score, developed by the OMERACT-EULAR-Ultrasound Task Force, predict disease activity outcomes in rheumatoid arthritis (RA). METHODS: Patients with RA who were methotrexate inadequate responders starting abatacept were evaluated. Individual joint PDUS scores were combined in the Global OMERACT-EULAR Synovitis Score (GLOESS) for metacarpophalangeal joints (MCPs) 2–5, all joints (22 paired) and a reduced (9 paired) joint set. The predictive value of changes in GLOESS at week 1–16 evaluations for clinical status and response (Disease Activity Score (DAS)28 (C reactive protein, CRP) <2.6; DAS28(CRP) ≤3.2; DAS28(CRP) ≥1.2 improvement) up to week 24, and correlations between DAS28 and GLOESS were assessed. RESULTS: Eighty-nine patients completed the 24-week treatment period. Changes in GLOESS (MCPs 2–5) from weeks 1 to 16 were unable to predict DAS28 outcomes up to week 24. However, significant improvements in GLOESS (MCPs 2–5) were observed at week 12 in patients with DAS28 ≥1.2 improvement at week 24 versus those who did not achieve that clinical response. In patients achieving DAS28 ≥1.2 improvement or DAS28 ≤3.2 at week 24, changes in GLOESS (22 and 9 paired joint sets) were greater in patients who already achieved DAS28 ≥1.2 at week 12 than in those who did not. No significant correlations were found between changes in DAS28 and GLOESS definitions at any time point. CONCLUSIONS: PDUS was not correlated with clinical status or response as measured by DAS28-derived criteria, and PDUS changes were not predictive of clinical outcome. The discrepancies require further exploration. TRIAL REGISTRATION NUMBER: NCT00767325; Results. |
format | Online Article Text |
id | pubmed-4860864 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-48608642016-05-12 Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study D'Agostino, Maria-Antonietta Boers, Maarten Wakefield, Richard J Berner Hammer, Hilde Vittecoq, Olivier Filippou, Georgios Balint, Peter Möller, Ingrid Iagnocco, Annamaria Naredo, Esperanza Østergaard, Mikkel Gaillez, Corine Le Bars, Manuela RMD Open Imaging OBJECTIVES: To explore whether changes in a composite (power Doppler/greyscale ultrasound (PDUS)) synovitis score, developed by the OMERACT-EULAR-Ultrasound Task Force, predict disease activity outcomes in rheumatoid arthritis (RA). METHODS: Patients with RA who were methotrexate inadequate responders starting abatacept were evaluated. Individual joint PDUS scores were combined in the Global OMERACT-EULAR Synovitis Score (GLOESS) for metacarpophalangeal joints (MCPs) 2–5, all joints (22 paired) and a reduced (9 paired) joint set. The predictive value of changes in GLOESS at week 1–16 evaluations for clinical status and response (Disease Activity Score (DAS)28 (C reactive protein, CRP) <2.6; DAS28(CRP) ≤3.2; DAS28(CRP) ≥1.2 improvement) up to week 24, and correlations between DAS28 and GLOESS were assessed. RESULTS: Eighty-nine patients completed the 24-week treatment period. Changes in GLOESS (MCPs 2–5) from weeks 1 to 16 were unable to predict DAS28 outcomes up to week 24. However, significant improvements in GLOESS (MCPs 2–5) were observed at week 12 in patients with DAS28 ≥1.2 improvement at week 24 versus those who did not achieve that clinical response. In patients achieving DAS28 ≥1.2 improvement or DAS28 ≤3.2 at week 24, changes in GLOESS (22 and 9 paired joint sets) were greater in patients who already achieved DAS28 ≥1.2 at week 12 than in those who did not. No significant correlations were found between changes in DAS28 and GLOESS definitions at any time point. CONCLUSIONS: PDUS was not correlated with clinical status or response as measured by DAS28-derived criteria, and PDUS changes were not predictive of clinical outcome. The discrepancies require further exploration. TRIAL REGISTRATION NUMBER: NCT00767325; Results. BMJ Publishing Group 2016-05-05 /pmc/articles/PMC4860864/ /pubmed/27175297 http://dx.doi.org/10.1136/rmdopen-2015-000237 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Imaging D'Agostino, Maria-Antonietta Boers, Maarten Wakefield, Richard J Berner Hammer, Hilde Vittecoq, Olivier Filippou, Georgios Balint, Peter Möller, Ingrid Iagnocco, Annamaria Naredo, Esperanza Østergaard, Mikkel Gaillez, Corine Le Bars, Manuela Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study |
title | Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study |
title_full | Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study |
title_fullStr | Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study |
title_full_unstemmed | Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study |
title_short | Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study |
title_sort | exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the appraise study |
topic | Imaging |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860864/ https://www.ncbi.nlm.nih.gov/pubmed/27175297 http://dx.doi.org/10.1136/rmdopen-2015-000237 |
work_keys_str_mv | AT dagostinomariaantonietta exploringanewultrasoundscoreasaclinicalpredictivetoolinpatientswithrheumatoidarthritisstartingabataceptresultsfromtheappraisestudy AT boersmaarten exploringanewultrasoundscoreasaclinicalpredictivetoolinpatientswithrheumatoidarthritisstartingabataceptresultsfromtheappraisestudy AT wakefieldrichardj exploringanewultrasoundscoreasaclinicalpredictivetoolinpatientswithrheumatoidarthritisstartingabataceptresultsfromtheappraisestudy AT bernerhammerhilde exploringanewultrasoundscoreasaclinicalpredictivetoolinpatientswithrheumatoidarthritisstartingabataceptresultsfromtheappraisestudy AT vittecoqolivier exploringanewultrasoundscoreasaclinicalpredictivetoolinpatientswithrheumatoidarthritisstartingabataceptresultsfromtheappraisestudy AT filippougeorgios exploringanewultrasoundscoreasaclinicalpredictivetoolinpatientswithrheumatoidarthritisstartingabataceptresultsfromtheappraisestudy AT balintpeter exploringanewultrasoundscoreasaclinicalpredictivetoolinpatientswithrheumatoidarthritisstartingabataceptresultsfromtheappraisestudy AT molleringrid exploringanewultrasoundscoreasaclinicalpredictivetoolinpatientswithrheumatoidarthritisstartingabataceptresultsfromtheappraisestudy AT iagnoccoannamaria exploringanewultrasoundscoreasaclinicalpredictivetoolinpatientswithrheumatoidarthritisstartingabataceptresultsfromtheappraisestudy AT naredoesperanza exploringanewultrasoundscoreasaclinicalpredictivetoolinpatientswithrheumatoidarthritisstartingabataceptresultsfromtheappraisestudy AT østergaardmikkel exploringanewultrasoundscoreasaclinicalpredictivetoolinpatientswithrheumatoidarthritisstartingabataceptresultsfromtheappraisestudy AT gaillezcorine exploringanewultrasoundscoreasaclinicalpredictivetoolinpatientswithrheumatoidarthritisstartingabataceptresultsfromtheappraisestudy AT lebarsmanuela exploringanewultrasoundscoreasaclinicalpredictivetoolinpatientswithrheumatoidarthritisstartingabataceptresultsfromtheappraisestudy |